Imperial Oil Limited Common Stock vs Tango Therapeutics Inc. — how do they compare? Imperial Oil Limited Common Stock trades at $130.2 (market cap $62.22B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Imperial Oil Limited Common Stock is far larger — about 16.6× Tango Therapeutics Inc.'s market cap, and Imperial Oil Limited Common Stock pays a 1.9% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals.
| IMO | TNGX | |
|---|---|---|
Market Cap | $62.22B | $3.75B |
Volume | 560,544 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $138.33 | $32.90 |
52-Week Low | $83.72 | $7.50 |
Enterprise Value | $63.13B | $2.77B |
Dividend Yield | 1.9% | — |
Typical Hold Time | — | 0 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Imperial Oil Limited is a Canadian integrated energy company that explores for and produces crude oil and natural gas, operates oil sands projects at Cold Lake, Kearl, and Syncrude, and refines and markets petroleum products under the Esso and Mobil brands. ExxonMobil Corporation holds a majority ownership stake in the company.
Read more on IMO →Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →